Navigation Links
ArterX™ Clinical Trial Results Announced at Veith Meeting
Date:11/18/2010

MOUNTAIN VIEW, Calif., Nov. 18, 2010 /PRNewswire/ -- US clinical trial results for Tenaxis' investigational vascular surgical sealant, ArterX, were presented today at the Veith Meeting in New York.  William M. Stone, MD of the Mayo Clinic, Scottsdale AZ reported a more than 20% margin of improvement for ArterX Surgical Sealant in the sealing of vascular suture lines compared with a control group featuring a commercially available gelatin foam/thrombin combination.

In a presentation titled "A Novel More Effective Glue-Sealant (ArterX) for Hemostasis at Vascular Suture Lines and Other Sites," Dr. Stone reported that ArterX Surgical Sealant achieved immediate hemostasis more than 60% of the time in a 217 patient clinical trial conducted at 11 different hospitals in the US.

President and CEO, David Smith, commented, "We are delighted with the preliminary results of our US clinical trial.  We were also able to show a statistically significant reduction in operating time of 36 minutes in the ArterX group, and ArterX patients were discharged from hospital after 4.1 days, an improvement of 1.3 days over the control group. If approved, we believe that ArterX Surgical Sealant will yield economic benefits for surgeons and hospitals that adopt it."

ArterX Surgical Sealant is currently under review by the FDA and is not available for sale in the USA.

ArterX is CE Marked in the European Union

About Tenaxis Medical, Inc.

Incorporated in 2004 and located in Mountain View, CA, Tenaxis Medical, Inc. is a privately held Company. It develops novel, high performance sealants for use in vascular and general surgery. In addition to the ArterX Surgical Sealant, the company is developing a second high performance sealant for use throughout the gastrointestinal tract, and an anti-adhesion agent that can be delivered  laparoscopically to help prevent or reduce pelvic and abdominal adhesions.Contact: Ronald Dieck+1-650-691-9016, ext. 110
'/>"/>

SOURCE Tenaxis Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
2. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Clinical Experts Describe Radiosurgical Advances for Brain, Breast, and Spinal Cancers
5. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
6. PAREXEL Wins Clinical Research Team of the Year Scrip Award
7. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
8. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
9. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
10. Frost & Sullivan Recognizes Merge Healthcares Clinical Imaging Management Solution as Game Changing Technology
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):